{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(3)"],"submitter":["Zhang L"],"pubmed_abstract":["Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identification of IDO1 inhibitors containing replacements or isosteres for the amide found in BMS-986205, an amide-containing, IDO1-selective inhibitor currently in phase III clinical trials. Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-containing IDO1 inhibitors."],"journal":["ACS medicinal chemistry letters"],"pagination":["494-501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7958151"],"repository":["biostudies-literature"],"pubmed_title":["Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy."],"pmcid":["PMC7958151"],"pubmed_authors":["Balog A","Huang C","Gullo-Brown J","Kopcho L","Borzilleri R","Johnston-Allegretto K","Padmanabhan S","Zhang L","Dhar G","Mahankali S","Murali V","Cherney EC","Li X","Rajanna P","Mariappan T","Fereshteh M","Vite G","Lin TA","Anandam A","Maley D","Zhu X","Hunt JT","Traeger SC"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.","description":"Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identification of IDO1 inhibitors containing replacements or isosteres for the amide found in BMS-986205, an amide-containing, IDO1-selective inhibitor currently in phase III clinical trials. Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-containing IDO1 inhibitors.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-19T12:53:47.851Z","creation":"2025-04-19T12:53:47.851Z"},"accession":"S-EPMC7958151","cross_references":{"pubmed":["33738077"],"doi":["10.1021/acsmedchemlett.1c00014"]}}